Skip to main content
 

Press Releases

October 8, 2015
Caribou and DuPont cross-license CRISPR-Cas intellectual property portfolios Caribou and DuPont enter into multi-year research collaboration to advance genome editing technology platform DuPont makes equity investment in Caribou
April 16, 2015

Caribou Biosciences, a developer of CRISPR-Cas9 technologies for precision cell engineering, today announced that co-founder Jennifer Doudna, Ph.D., has been named to TIME magazine's TIME 100 - TIME's annual list of the 100 most influential people in the world. Dr. Doudna is being recognized for harnessing CRISPR-Cas systems to establish a transformative gene-editing technology platform.

April 2, 2015

Caribou Biosciences, a developer of CRISPR-Cas9 technologies for precision cell engineering, today announced that it has closed an $11 million Series A financing round. Investors include Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, and an undisclosed strategic partner. In addition, Dr. Jennifer Doudna, Investigator, Howard Hughes Medical Institute, Professor, U.C. Berkeley and co-founder of Caribou, also joined the round as an investor.

January 15, 2015
Data presented at Keystone Symposium for Precision Genome Engineering and Synthetic Biology

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced the presentation of new findings demonstrating the advancement of its proprietary CRISPR-Cas9 gene editing and repair technology platform. These findings were presented this week in two poster sessions at The Keystone Symposium for Precision Genome Engineering and Synthetic Biology in Big Sky, Montana.

January 7, 2015
Companies to explore promise of CRISPR as a drug discovery research tool

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced that it entered into a collaboration agreement with Novartis under which the two companies will utilize Caribou's proprietary CRISPR-Cas9 platform to research new CRISPR-based drug target screening and validation technologies.

Pages